Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|EGFRBi-armed autologous activated T cells||EGFR Antibody 30||EGFRBi-armed autologous activated T cells are autologous T-cells that have been "armed" with a bispecific antibody that binds EGFR and CD3, potentially enhancing T-cell mediated response to EGFR-expressing cells upon antibody binding (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT00569296||Phase I||Aldesleukin + EGFRBi-armed autologous activated T cells + Sargramostim||Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer||Terminated|